Clinical trials
Suspended Phase 1/2 trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
108 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 4 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 7 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 12 |
| 2022 | 12 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 12 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Suspended | 108 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| Sclnow Biotechnology Co., Ltd. | 4 |
| M.D. Anderson Cancer Center | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| City of Hope Medical Center | 2 |
| Healeon Medical Inc | 2 |
| Hokkaido Gastrointestinal Cancer Study Group | 2 |
| Innovent Biologics (Suzhou) Co. Ltd. | 2 |
| Mansoura University | 2 |
| University of Chicago | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 9 |
| Pancreatic Neoplasms | 6 |
| Multiple Myeloma | 5 |
| Myelodysplastic Syndromes | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Brain Neoplasms | 3 |
| Glioblastoma | 3 |
| Leukemia | 3 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Melanoma | 3 |
Trials
Showing 26 to 50 of 108. Each trial links to its page on Pharma Observatory.
8 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.